H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO) Jun 16, 2026 06:43AM
Halozyme expects minimal Medicare pricing impact on royalties through 2035 Jun 15, 2026 06:01AM
Benchmark Reiterates Buy Rating on Halozyme Therapeutics (HALO) on Near-Term Potential Jun 3, 2026 09:02AM
Increasing unusual call option volume: MRAM HALO DGXX DT SGI CM KOPN May 13, 2026 05:40AM
Halozyme Therapeutics (HALO) Reiterated at Market Outperform by Citizens on Beating Q1 Estimates May 12, 2026 05:47AM
View Older Stories

May 11, 2026 04:20PM Halozyme Therapeutics (HALO)
May 11, 2026 04:03PM Halozyme Therapeutics (HALO) Tops Q1 EPS by 6c
Apr 29, 2026 06:59AM Halozyme Therapeutics (HALO) PT Raised to $95 at H.C. Wainwright
Apr 13, 2026 08:39AM TD Cowen Reiterates Top Pick on Halozyme Therapeutics (HALO)
Apr 7, 2026 11:08AM Leerink Partners on Halozyme Therapeutics (HALO): VRTX partnership 'validation of Hypercon'
Apr 7, 2026 08:05AM Halozyme licenses drug delivery technology to Vertex for $15 million
Feb 19, 2026 10:25AM Halozyme Therapeutics (HALO) PT Raised to $90 at Benchmark Following Strong Q4 Results
Feb 18, 2026 08:14AM Halozyme Therapeutics (HALO) PT Raised to $96 at TD Cowen
Feb 17, 2026 04:06PM Halozyme Therapeutics (HALO) Misses Q4 EPS by 214c ; Offers Guidance
Feb 3, 2026 09:29AM Benchmark Reiterates Buy Rating on Halozyme Therapeutics (HALO) Following Raised Guidance
Jan 29, 2026 06:49AM H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)
Jan 29, 2026 04:44AM Goldman Sachs Reiterates Sell Rating on Halozyme Therapeutics (HALO)
Jan 28, 2026 06:41AM Halozyme provides preliminary 2025 revenue estimates
Jan 8, 2026 09:30AM Halozyme Therapeutics (HALO) PT Raised at TD Cowen; 'One of Our Top Picks for 2026'
Dec 5, 2025 05:18AM Halozyme (HALO) Has Compelling Upside Driver in MDASE royalty - Citizens
Dec 4, 2025 01:28PM German court grants HALOZYME injunction against Merck's Keytruda SC
Dec 4, 2025 06:51AM Goldman Sachs Downgrades Halozyme Therapeutics (HALO) to Sell 'as we approach peak revenue'
Nov 28, 2025 06:34AM H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)
Nov 17, 2025 11:21AM Halozyme Therapeutics (HALO) PT Raised to $56 at Goldman Sachs
Nov 7, 2025 08:31AM FDA approves DARZALEX Faspro for high-risk smoldering multiple myeloma
Nov 4, 2025 05:03AM Halozyme Therapeutics (HALO) PT Raised to $92 at Citizens on Strong Quarter
Nov 3, 2025 04:02PM Halozyme Therapeutics (HALO) Tops Q3 EPS by 11c, provides guidance
Oct 21, 2025 06:46AM H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)
Oct 14, 2025 01:26PM Leerink Partners Upgrades Halozyme Therapeutics (HALO) to Market Perform
Oct 2, 2025 06:42AM Halozyme Therapeutics (HALO) PT Raised to $90 at H.C. Wainwright
Oct 2, 2025 04:28AM Halozyme Therapeutics (HALO) PT Raised to $70 at Leerink Partners
Oct 1, 2025 01:20PM Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
Oct 1, 2025 01:13PM FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
Oct 1, 2025 04:21AM Citizens JMP Reiterates Market Outperform Rating on Halozyme Therapeutics (HALO)
Sep 24, 2025 08:20AM Halozyme Therapeutics (HALO) PT Raised to $90 at Benchmark Following Strong Earnings, Guidance
Sep 22, 2025 06:42AM Halozyme Therapeutics (HALO) PT Raised to $85 at H.C. Wainwright
Aug 12, 2025 04:59AM Halozyme Therapeutics (HALO) PT Raised to $56 at Goldman Sachs
Aug 6, 2025 04:08AM Halozyme Therapeutics (HALO) PT Raised to $91 at Citizens JMP
Aug 6, 2025 03:37AM Morgan Stanley Upgrades Halozyme Therapeutics (HALO) to Overweight
Aug 5, 2025 04:05PM Halozyme Therapeutics (HALO) Tops Q2 EPS by 30c ; Offers Guidance
Jul 23, 2025 11:39AM European Commission approves Halozyme's DARZALEX Faspro for smouldering multiple myeloma
Jul 10, 2025 06:28AM Goldman Sachs Resumes Halozyme Therapeutics (HALO) at Neutral
Jun 30, 2025 04:07PM Halozyme Therapeutics (HALO) added to Russell 1000
Jun 20, 2025 01:15PM Halozyme Therapeutics (HALO) Announces argenx Received European Commission Approval for VYVGART Subcutaneous Injection with ENHANZE
Jun 10, 2025 10:00AM TD Cowen on Halozyme Therapeutics (HALO): 'Potential CMS Impact Analysis Reaffirms Our Buy Rating'
May 29, 2025 06:54AM H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)
May 28, 2025 08:31AM Halozyme Therapeutics (HALO) Announces Bristol Myers Squibb (BMY) Received European Commission Approval for Subcutaneous Opdivo Co-Formulated with ENHANZE
May 14, 2025 04:50AM Increasing unusual call option volume: PSX XLI HALO ARRY SATS SHLS AVTR
May 14, 2025 04:13AM Citizens JMP Reiterates Market Outperform Rating on Halozyme Therapeutics (HALO)
May 14, 2025 03:12AM Morgan Stanley Downgrades Halozyme Therapeutics (HALO) to Equalweight
May 13, 2025 02:44PM Evercore ISI Reiterates Outperform Rating on Halozyme Therapeutics (HALO)
May 13, 2025 08:50AM Leerink Partners Downgrades Halozyme Therapeutics (HALO) to Underperform 'On CMS Action'
May 7, 2025 10:47AM Benchmark Reiterates Hold Rating on Halozyme Therapeutics (HALO)
May 6, 2025 11:36PM Halozyme Therapeutics (HALO) PT Raised to $79 at TD Cowen
May 6, 2025 04:17PM Halozyme Therapeutics (HALO) Tops Q1 EPS by 13c, provides guidance
View Older Stories